SavedAdd your journal

Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2006 / Cilt: 16 - Sayı: 3

Fondaparinux treatment in heparin induced thrombocytopenia: Case report

Heparinin indüklediği trombositopenide fondaparinux tedavisi: Olgu sunumu

TÜLİN AKAGÜN
MEHMET SÖNMEZ
Mustafa YILMAZ
ELİF AKDOĞAN
Ahmet DURMUŞ
Ercüment OVALI
Serdar B. OMAY
Pages
141–144
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We tried to make an overview of new treatment choices.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Heparin induced thrombocytopenia (HIT) is a complication of heparin therapy, that is associated with thrombocytopenia, arterial and venous thromboembolism.
📊
Key Findings & Data:HIT usually develops 5 and 14 days after commencement of heparin therapy.
💡
Conclusion & Impact:We tried to make an overview of new treatment choices.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Tedavi sonucu · Ergen · Kadın

Abstract

Heparin induced thrombocytopenia (HIT) is a complication of heparin therapy, that is associated with thrombocytopenia, arterial and venous thromboembolism. HIT usually develops 5 and 14 days after commencement of heparin therapy. HIT is a situation that has high mortality if it is not treated. When HIT is suspected, all forms of heparin should be discontinued and treatment with a direct thrombin inhibitor should be initiated. Fondaparinux is a synthetic pentasaccharide anticoagulant drug which is used for the treatment of HIT. Our case represents thrombocytopenia / thrombosis as a complication of heparin therapy. We tried to make an overview of new treatment choices.

Özet

Heparinin indüklediği trombositopeni (HIT); heparin tedavisinin trombositopeni, arteriyel ve venöz tromboembolilerle seyreden en önemli komplikasyonudur. Genellikle heparin tedavisinin 5-14. günlerinde görülür. Tedavi edilmediğinde mortalitesi oldukça yüksek olan bu tabloda, tedavi öncelikle heparinin kesilmesi ve tromboembolik komplikasyonlara yönelik direkt trombin inhibitörlerinin kullanılmasıdır. Fondaparinux, HIT tedavisinde kullanılabileceği belirtilen sentetik pentasakkarit yapısında antikoagülan bir ilaçtır. Bu olguda heparin tedavisinin bir komplikasyonu olarak ortaya çıkan trombositopeni / tromboz tablosu (HIT) ve yeni tedavi yaklaşımları ile ilgili literatür bilgilerinin gözden geçirilmesi amaçlanmıştır.

🔖

Cite This Article

AKAGÜN, T., SÖNMEZ, M., YILMAZ, M., AKDOĞAN, E., DURMUŞ, A., OVALI, E., OMAY, S. B. (2006). Fondaparinux treatment in heparin induced thrombocytopenia: Case report. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 16 - Sayı: 3, 141–144. https://ajindex.com/articles/323057

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Deitcher S, Rodgers G. Thrombosis and Antithrombotic Therapy. In: Wintrobe’s Clinical Hematology. Greer JP, Foerster J, Lukens JN, et al (eds). Philadelphia, Lippincott Williams- Wilkins 2004: 1713-1758
  2. Spinler SA. New Concepts in Heparin-Induced Thrombocytopenia: Diagnosis and Management. J Thromb Thrombolysis 21(1): 17-21, 2006
  3. Matsuo T, Wanaka K, Asada R. Heparin-induced thrombocytopenia (HIT): pathogenesis, laboratory test, and treatment. Rinsho Byori 53(7): 622-9, 2005
  4. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (3 Suppl): 311S-337S, 2004
  5. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 101(5):502-7, 1996
  6. Refaai MA, Van Cott EM, Laposata M. The timing of a positive test result for heparin- induced thrombocytopenia relative to the platelet count and anticoagulant therapy in 43 consecutive cases. Am J Clin Pathol 119: 497-504, 2003
  7. Kuo KH, Kovacs MJ. Fondaparinux: A potential new therapy for HIT. Hematology, 10(4): 271-5, 2005
  8. Francis CW. Direct thrombin inhibitors for treatment of heparin induced thrombocytopenia, deep vein thrombosis and atrial fibrillation. Curr Pharm Des 11(30): 3931-41, 2005
  9. Betrosian A, Theodossiades G, Lambroulis G, et al Heparin-Induced Thrombocytopenia with Pulmonary Embolism and Disseminated Intravascular Coagulation Associated with Low- Molecular-Weight Heparin: Am J Med Sci, 325 (1): 45-47, 2003
  10. Arixtra (fondaparinux sodium) Injection Prescribing Information. GlaxoSmithKline, Research Triangle Park, MC; May 2005
  11. Savi P, Chong BH, Greinacher A, et al. Effect of fondaparinux on platelet activation in presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 105: 139-144, 2005
  12. Ahmad S, Jeske WP, Walenga JM, et al. Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Clin Appl Thromb Hemost 5(4): 259- 266, 1999.